CN101677556A - 治疗cb2受体介导的疼痛的方法 - Google Patents

治疗cb2受体介导的疼痛的方法 Download PDF

Info

Publication number
CN101677556A
CN101677556A CN200880016433A CN200880016433A CN101677556A CN 101677556 A CN101677556 A CN 101677556A CN 200880016433 A CN200880016433 A CN 200880016433A CN 200880016433 A CN200880016433 A CN 200880016433A CN 101677556 A CN101677556 A CN 101677556A
Authority
CN
China
Prior art keywords
halogen
optionally substituted
aryl
alkyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880016433A
Other languages
English (en)
Chinese (zh)
Inventor
M·夏
C·M·弗洛尔斯
M·J·马切拉格
K·P·帕夫利克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39766329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101677556(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN101677556A publication Critical patent/CN101677556A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN200880016433A 2007-03-21 2008-02-27 治疗cb2受体介导的疼痛的方法 Pending CN101677556A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89601407P 2007-03-21 2007-03-21
US60/896,014 2007-03-21
PCT/US2008/055084 WO2008115671A1 (en) 2007-03-21 2008-02-27 Method for treating cb2 receptor mediated pain

Publications (1)

Publication Number Publication Date
CN101677556A true CN101677556A (zh) 2010-03-24

Family

ID=39766329

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880016433A Pending CN101677556A (zh) 2007-03-21 2008-02-27 治疗cb2受体介导的疼痛的方法

Country Status (14)

Country Link
US (1) US20080234347A1 (cg-RX-API-DMAC7.html)
EP (1) EP2139326A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010522181A (cg-RX-API-DMAC7.html)
KR (1) KR20090120499A (cg-RX-API-DMAC7.html)
CN (1) CN101677556A (cg-RX-API-DMAC7.html)
AR (1) AR065800A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008229264A1 (cg-RX-API-DMAC7.html)
CA (1) CA2681381A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008000827A1 (cg-RX-API-DMAC7.html)
MX (1) MX2009010162A (cg-RX-API-DMAC7.html)
PE (1) PE20090062A1 (cg-RX-API-DMAC7.html)
TW (1) TW200901972A (cg-RX-API-DMAC7.html)
UY (1) UY30973A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008115671A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110545802A (zh) * 2017-11-15 2019-12-06 帕纳格制药公司 间质性膀胱炎的治疗方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102282147B (zh) * 2009-01-28 2015-09-30 卡拉治疗学股份有限公司 二环吡唑并-杂环
CN122555695A (zh) 2023-11-29 2026-08-11 爱克堤欧生物科学股份有限公司 可用作kcnt1抑制剂的杂环化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005063241A1 (ja) * 2003-12-26 2007-07-19 小野薬品工業株式会社 ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および/または治療剤
US7452997B2 (en) * 2004-03-24 2008-11-18 Janssen Pharmaceutica, N.V. Tetrahydro-indazole cannabinoid modulators
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
ES2375213T3 (es) * 2005-09-23 2012-02-27 Janssen Pharmaceutica Nv Moduladores de cannabinoides de hexadhidro-cicloheptapirazol.
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110545802A (zh) * 2017-11-15 2019-12-06 帕纳格制药公司 间质性膀胱炎的治疗方法

Also Published As

Publication number Publication date
AR065800A1 (es) 2009-07-01
CL2008000827A1 (es) 2008-09-26
KR20090120499A (ko) 2009-11-24
JP2010522181A (ja) 2010-07-01
CA2681381A1 (en) 2008-09-25
MX2009010162A (es) 2009-10-12
TW200901972A (en) 2009-01-16
UY30973A1 (es) 2008-09-30
AU2008229264A1 (en) 2008-09-25
WO2008115671A1 (en) 2008-09-25
EP2139326A1 (en) 2010-01-06
PE20090062A1 (es) 2009-01-26
US20080234347A1 (en) 2008-09-25
EP2139326A4 (en) 2011-06-15

Similar Documents

Publication Publication Date Title
RU2585095C2 (ru) Применение сигма-лигандов от боли при раке костей
AU2011212389B2 (en) Sigma ligands for use in the prevention and/or treatment of postoperative pain
US9931346B2 (en) Serotonin-norepinephrine reuptake inhibitors (SNRIs) and Sigma receptor ligands combinations
CN105873580B (zh) 加巴喷丁类化合物与σ受体配体的组合物
KR20120089287A (ko) 통증 치료에 있어서 트라마돌 및 셀레콕시브를 포함하는 조성물
AU2014255837A1 (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
JP2010522181A (ja) Cb2受容体介在疼痛を処置する方法
AU2008229265A1 (en) Method for treating CB2 receptor mediated pain
CN101312952B (zh) 四氢-环戊二烯并吡唑大麻素调节剂
WO2014173903A1 (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
US20090215850A1 (en) Method for treating cb2 receptor mediated pain
JP2005526695A (ja) シブトラミンおよびそれの代謝物の2−ヒドロキシ誘導体の製造方法および使用方法
WO2010079255A1 (es) Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
HK1254202B (en) Triazole derivatives
EP4713325A1 (en) Particles of imidazo [4,5-b] pyridine compound, pharmaceutical compositions, and their use in treating medical conditions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100324